During the past few years, we witnessed explosive progress in the field of stem cell research, leading to an increasing hope for more effective cell replacement therapies to treat various diseases. The self-renewal capability of stem cells, combined with their ability to differentiate into different cell types under programmed conditions, enables improved models for drug discovery and mechanism-based studies of diseases, hence laying the foundation for their therapeutic applications1. In fact, induced pluripotent stem cell (iPSC)-based transplantation therapy has already been performed in rodent models2.
The examples of major progress are seen in the multiple fronts. Active small molecules have been identified to promote stem cell self-renewal, proliferation, differentiation and somatic cell reprogramming3. The effective applications of iPSC technology open a new path for cell replacement therapies and drug screening. Furthermore, patient-specific iPSCs and subsequently differentiated cells manifesting disease phenotypes allow reconstitution of human disease pathology in cell culture, thus offer precious opportunities to investigate human proteins in the native cellular context. The benefits of investigating human proteins provide the opportunities to evaluate both general toxicity for therapeutics and, more excitingly, to test drug effects under specific genetic background. In many ways, these options are more physiologically relevant and cost-effective than animal models.
This special issue includes eleven articles that highlight both new findings and emerging ideas in different aspects of stem cell technologies4,5, clinical therapy6,7,8,9,10 and drug discovery11,12,13,14. The ensemble of these impressive articles provides an excellent reference map for the experts and a point of entry into this exciting research field for the novice. It is evident that stem cell research has evolved from a subject of basic experimental biology to a highly sophisticated, penetrating scientific establishment that is poised to catalyze translational medicine bringing research findings in laboratories to patient benefits in clinic.
References
Maury Y, Gauthier M, Peschanski M, Martinat C . Human pluripotent stem cells for disease modelling and drug screening. Bioessays 2012; 34: 61–71.
Hanna J, Wernig M, Markoulaki S, Sun CW, Meissner A, Cassady JP, et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 2007; 318: 1920–3.
Huangfu D, Maehr R, Guo W, Eijkelenboom A, Snitow M, Chen AE, et al. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat Biotechnol 2008; 26: 795–7.
Su JB, Pei DQ, Qin BM . Roles of small molecules in somatic cell reprogramming. Acta Pharmacol Sin 2013; 34: 719–24.
Wu B, Li W, Wang L, Liu ZH, Zhao XY . Stem cells and small molecule screening: haploid embryonic stem cells as a new tool. Acta Pharmacol Sin 2013; 34: 725–31.
Chen K, Huang YH, Chen JL . Understanding and targeting cancer stem cells: therapeutic implications and challenges. Acta Pharmacol Sin 2013; 34: 732–40.
Xu XL, Yi F, Pan HZ, Duan SL, Ding ZC, Yuan GH, et al. Progress and prospects in stem cell therapy. Acta Pharmacol Sin 2013; 34: 741–6.
Wei X, Yang X, Han ZP, Qu FF, Shao L, Shi YF . Mesenchymal stem cells: a new trend for cell therapy. Acta Pharmacol Sin 2013; 34: 747–54.
Lin QM, Zhao S, Zhou LL, Fang XS, Fu Y, Huang ZT . Mesenchymal stem cells transplantation suppresses inflammatory responses in global cerebral ischemia: contribution of TNF-α-induced protein 6. Acta Pharmacol Sin 2013; 34: 784–92.
Rao GH, Liu HM, Li BM, Hao JJ, Yang YL, Wang MR, et al. Establishment of a human colorectal cancer cell line P6C with stem cell properties and resistance to chemotherapeutic drugs. Acta Pharmacol Sin 2013; 34: 793–804.
Xu XH, Zhong Z . Disease modeling and drug screening for neurological diseases using human induced pluripotent stem cells. Acta Pharmacol Sin 2013; 34: 755–64.
Zhang R, Zhang LH, Xie X . iPSCs and small molecules: a reciprocal effort towards better approaches for drug discovery. Acta Pharmacol Sin 2013; 34: 765–76.
An SM, Ding QP, Li LS . Stem cell signaling as a target for novel drug discovery: recent progress in the WNT and Hedgehog pathways. Acta Pharmacol Sin 2013; 34: 777–83.
Liu X, Zhang Y, Tong M, Liu XY, Luo GZ, Xie DF, et al. Identification of a small molecule 1,4-bis-[4-(3-phenoxy-propoxy)-but-2-ynyl]-piperazine as a novel inhibitor of the transcription factor p53. Acta Pharmacol Sin 2013; 34: 805–10.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zhou, Q. Progress and prospects in stem cell therapy and drug discovery. Acta Pharmacol Sin 34, 717–718 (2013). https://doi.org/10.1038/aps.2013.72
Published:
Issue Date:
DOI: https://doi.org/10.1038/aps.2013.72
This article is cited by
-
Expression profiles of histone lysine demethylases during cardiomyocyte differentiation of mouse embryonic stem cells
Acta Pharmacologica Sinica (2014)
